Opinion|Videos|April 15, 2025
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.
Advertisement
Episodes in this series
Advertisement
Related to this article
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Advertisement
Advertisement
Trending on Dermatology Times
1
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
2
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
5